Core Points - The company has issued a special report on the use of raised funds as of June 30, 2025, ensuring the information is true, accurate, and complete [1] - The company raised a total of RMB 276 million through the issuance of convertible bonds in March 2022 and RMB 301.99 million through a private placement of A-shares in September 2023 [2][5] - The company has established a fund management system to ensure the effective use of raised funds and protect investor rights [2][3] Fundraising Overview - The total amount raised from the convertible bonds was RMB 276 million, with a net amount of RMB 272 million after deducting issuance costs [1] - The total amount raised from the A-share issuance was RMB 301.99 million, with a net amount of RMB 294.84 million after deducting issuance costs [2] - As of June 30, 2025, the company has used a total of RMB 421.71 million of the raised funds, with RMB 155.79 million remaining [5][6] Fund Management and Usage - The company has implemented a dedicated account management system for the raised funds, ensuring compliance with relevant laws and regulations [2][3] - As of June 30, 2025, several fundraising accounts have been closed, and the remaining funds are stored in dedicated accounts [3][4] - The company has not engaged in any temporary use of idle funds for working capital or cash management [5][6] Project Updates and Changes - The "Construction Project of Centralized Preparation Center for Medical Institutions in Shaanxi Province" has been delayed and the completion date has been extended to December 31, 2024, due to various factors [6][9] - The company has decided to terminate the project and use the remaining funds for permanent working capital, following board and supervisory approvals [6][9] - The company has also terminated the "Quality Inspection and Testing Shared Platform Upgrade Project" and redirected the remaining funds to working capital [6][9] Compliance and Disclosure - The company has ensured that all fundraising activities and fund usage have been disclosed in a timely, truthful, accurate, and complete manner [5][6] - There have been no violations in the management of raised funds during the reporting period [5][6]

陕西盘龙药业集团股份有限公司独立董事工作制度 陕西盘龙药业集团股份有限公司 （2025 年 月） 第一章 总则 第一条 根据《中华人民共和国公司法》（以下简称"公司法"）、《中华 人民共和国证券法》、《上市公司独立董事管理办法》、《深圳证券交易所上市 公司自律监管指引第 1 号—主板上市公司规范运作（2025 年修订）》（以下简 称"监管指引"）的规定，为进一步完善陕西盘龙药业集团股份有限公司（以下 简称"公司"）的法人治理结构，强化对内部董事及经理层的约束和监督机制， 保护中小股东及债权人的利益，促进公司的规范运作，制定本制度。 第二条 独立董事是指不在公司担任除独立董事外的任何其他职务，并与公 司及公司主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能妨 碍其进行独立客观判断关系的董事。 第三条 公司建立独立董事制度。独立董事制度应当符合法律、行政法规和 《上市公司独立董事管理办法》的规定，有利于上市公司的持续规范发展、不得 损害上市公司利益。公司应当为独立董事依法履职提供必要保障。 第四条 公司董事会成员中应当有三分之一或以上为独立董事，且其中至少 有一名会计专业人士（会计专业人士是指具有高级 ...

Core Points - The document outlines the rules governing the board of directors of Shaanxi Panlong Pharmaceutical Group Co., Ltd, aiming to clarify responsibilities, ensure efficient decision-making, and protect the interests of shareholders [1][2]. Group 1: General Provisions - The board of directors is a permanent body responsible for executing shareholder resolutions and making significant operational decisions [2]. - The rules are established in accordance with the Company Law of the People's Republic of China and relevant regulations [1][2]. Group 2: Board Composition and Responsibilities - Directors must be natural persons and cannot be nominated if they fall under specific disqualifying conditions, such as administrative penalties from the China Securities Regulatory Commission [3][4]. - The board must include employee representatives, elected through democratic processes [6]. - Directors serve a term of three years and can be re-elected, with provisions for their removal only under specific circumstances [6][9]. Group 3: Duties and Obligations of Directors - Directors are required to act in the best interests of the company, avoiding conflicts of interest and ensuring transparency in their dealings [10][11]. - They must disclose any potential conflicts and adhere to strict confidentiality regarding company secrets [7][11]. - Directors are obligated to attend meetings and provide written explanations if they miss meetings [9][12]. Group 4: Board Meetings - The board must hold at least two regular meetings annually, with provisions for special meetings upon request from shareholders or directors [28][29]. - Meeting notifications must include detailed agendas and relevant materials to ensure informed decision-making [30][31]. - Decisions require a majority vote from attending directors, and specific matters must receive prior approval from independent directors [66][63]. Group 5: Committees and Special Provisions - The board may establish specialized committees, such as audit and remuneration committees, to enhance governance [12][21]. - Independent directors play a crucial role in overseeing compliance and reporting any irregularities to the board [20][63]. - The chairman of the board is responsible for ensuring the effective operation of the board and compliance with these rules [42][46].

陕西盘龙药业集团股份有限公司董事会薪酬与考核委员会实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员的考核 和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》、 《陕西盘 龙药业集团股份有限公司章程》 （以下简称"公司章程"）等规定，公司特设置董 事会薪酬与考核委员会，并制定本实施细则。 第二条 薪酬与考核委员会是董事会按照股东会决议设置的专门工作机构， 主要负责制定、审查公司董事、高级管理人员的薪酬政策与方案，负责制定公司 董事及高级管理人员的考核标准并进行考核，对董事会负责。 第三条 本细则所称董事是指在本公司领取薪酬的董事，高级管理人员是指 董事会聘任的总裁、副总裁、财务负责人、董事会秘书。 第二章 人员组成 第四条 薪酬与考核委员会由三名董事组成，独立董事过半数并担任召集人。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体 董事的三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员一名，由独立董事担任，负责主持委 员会的工作。主任委员在委员内选举，并报请董事会备案 ...

陕西盘龙药业集团股份有限公司董事会提名委员会实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公司治理结构， 根据《中华人民共和国公司法》、《陕西盘龙药业集团股份有限公司章程》（以下 简称"公司章程"）等有关规定，公司设立董事会提名委员会，并制定本议事规 则。 第二条 董事会提名委员会是董事会按照股东会决议设置的专门工作机构， 主要负责对公司董事、高级管理人员的人选、选择标准和程序进行选择并提出建 议，直接对董事会负责。 第二章 人员组成 第三条 提名委员会委员由三名董事组成，其中独立董事过半数并担任召集 人。 第四条 提名委员会委员由董事长、二分之一以上独立董事或全体董事的三 分之一提名，并由董事会选举产生。 第五条 提名委员会设主任委员一名，由独立董事担任，主任委员负责主持 委员会工作；主任委员在委员内选举，并报董事会备案。 （三）法律、行政法规、中国证监会及公司章程规定的其他事宜。 第九条 提名委员会的提案提交董事会审议决定。 第四章 决策程序 第六条 提名委员会任期与董事会任期一致，委员任期届满连选可以连任。 期间如有 ...

Core Viewpoint - The implementation rules for the Audit Committee of Shaanxi Panlong Pharmaceutical Group Co., Ltd. aim to enhance the decision-making function of the board, ensure effective supervision of the management, and improve the corporate governance structure [1]. Group 1: General Provisions - The Audit Committee is established as a specialized working body of the board, responsible for communication, supervision, and verification of internal and external audits [1]. - The company must provide necessary working conditions for the Audit Committee, including dedicated personnel or institutions for daily operations [1]. Group 2: Composition of the Committee - The Audit Committee consists of three directors, with a majority being independent directors, and may include employee representatives [2]. - The chairperson of the Audit Committee must be an independent director with accounting expertise [2]. Group 3: Responsibilities and Authority - The main responsibilities of the Audit Committee include supervising and evaluating external and internal audits, reviewing financial information, and ensuring compliance with laws and regulations [3]. - The Audit Committee must approve significant matters, such as financial disclosures and the hiring or dismissal of external auditors, before submission to the board [3][4]. Group 4: Decision-Making and Disclosure Procedures - The Audit Committee is responsible for reporting necessary measures or improvements to the board and making recommendations [4]. - The company must disclose the Audit Committee's annual performance in its annual report, including specific duties and meeting occurrences [8]. Group 5: Meeting Rules - The Audit Committee meetings must be held at least quarterly, with a quorum of two-thirds of members required for decisions [10]. - Meeting records must be accurate and complete, reflecting the opinions of attendees, and must be signed by the participants [11].

陕西盘龙药业集团股份有限公司董事、高级管理人员离职管理制度 陕西盘龙药业集团股份有限公司 董事、高级管理人员离职管理制度 （2025 年 8 月） 第一章 总则 第一条 为规范陕西盘龙药业集团股份有限公司（以下简称"公司"）董事、 高级管理人员离职相关事宜，确保公司治理结构的稳定性和连续性，维护公司及 股东的合法权益，公司根据《中华人民共和国公司法》（以下简称"《公司法》"） 等法律法规、规范性文件及《陕西盘龙药业集团股份有限公司章程》（以下简称 "《公司章程》"）的有关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事（含独立董事）、高级管理人员因任期届满、 辞职、被解除职务或其他原因离职的情形。 第五条 董事提出辞任的，公司应当在 60 日内完成补选，确保董事会及其专 门委员会构成符合法律、行政法规和《公司章程》的规定。 第六条 公司董事、高级管理人员在任职期间出现下列情形的，公司应当依 法解除其职务： 第二章 离职情形与程序 第三条 公司董事和高级管理人员可以在任期届满以前辞任，董事和高级管 理人员辞任应当向公司提交书面辞职报告，辞职报告中应说明辞任时间、辞任原 因、辞去的职务、辞任后是 ...

《上市公司治理准则》、 《陕西盘龙药业集团股份有限公司公司章程》（以下简称"公司章程"）等规定， 公司董事会下设董事会可持续战略发展委员会，并制定本实施细则。 陕西盘龙药业集团股份有限公司董事会可持续战略发展委员会实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司治理结构，根据《中华人民共和国公司法》、 第二条 董事会可持续战略发展委员会是董事会按照股东会决议设置的专 门工作机构，主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 可持续战略发展委员会由三名董事组成，其中应至少包括一名独立 董事。 第四条 可持续战略发展委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一提名，并由董事会选举产生。 第五条 可持续战略发展委员会设主任委员一名，负责主持可持续战略发展 委员会工作，由委员选举产生，并报董事会备案。 第六条 可持续战略发展委员会任期与董事会任期一致，委员任期届满，连 选可以 ...

General Principles - The rules are established to strengthen the management of shares held by directors and senior management of Shaanxi Panlong Pharmaceutical Group Co., Ltd. and to maintain market order [1] - The rules are based on relevant laws and regulations including the Company Law and Securities Law of the People's Republic of China [1] Share Management - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or during investigations related to securities violations [3] - The maximum amount of shares that can be transferred by directors and senior management in a year is limited to 25% of their total holdings, with exceptions for certain circumstances [4] - Newly acquired shares can only be transferred at a rate of 25% in the year they are acquired, and any increase in shares due to company actions will proportionally increase the transferable amount [4] Disclosure Requirements - Directors and senior management must report their share transactions to the company and disclose relevant information to the stock exchange within two trading days of any change [12] - A detailed plan must be disclosed prior to any share reduction, including the number of shares, time frame, and reasons for the reduction [5][7] - Any shareholding changes due to court-ordered transactions must be disclosed within two trading days of receiving the execution notice [6] Additional Regulations - Directors and senior management must ensure that their immediate family members and related parties do not engage in insider trading [24] - The rules apply to various scenarios including share increases due to capital increases or stock options [18] - The company is responsible for ensuring the accuracy and timeliness of the reported data [25]

陕西盘龙药业集团股份有限公司总裁工作细则 指引第 1 号—主板上市公司规范运作》、《陕西盘龙药业集团股份有限公司章程》 （以下简称"公司章程"）的有关规定，制定本细则。 第二条 公司依法设置总裁。 第三条 总裁由董事会聘任或者解聘，对董事会负责，根据公司章程的规定 或者董事会的授权行使职权。总裁列席董事会会议。 第四条 总裁主持公司日常生产经营和管理工作，组织实施董事会决议。 第二章 总裁的任职资格与任免程序 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 按照建立现代企业制度的要求，进一步完善陕西盘龙药业集团股份 有限公司（以下简称"公司"或"本公司"）治理结构，根据《中华人民共和国 公司法》、 《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管 第五条 总裁应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营 管理能力； （二）具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统 揽全局的能力； （三）具有一定年限的企业管理或经济工作经历，精通本行业、熟悉多种行 业的生产经营业务和掌握国家有关政策、法律、法规； （四） ...